The SLC6A4 gene encodes the serotonin transporter, the target of an important class of antidepressant drugs (serotonin selective reuptake inhibitors). Polymorphisms in the SLC6A4 gene have been reported to be associated with susceptibility to depression and other psychiatric disorders. We have constructed a 1 Mb YAC and PAC contig which harbours both the SLC6A4 and the carboxypeptidase D (CPD) genes. The order of loci within the contig was cen-D17S975-D17S1549-24R-D17S1294-SLC6A4-28L-(CPD, D17S2009, D17S2004)-D17S2120-ter. Both genes were deleted in one of 17 neurofibromatosis type 1 (NF1) patients carrying submicroscopic NF1 contiguous gene deletions.
Introduction
The actions of the neurotransmitter serotonin (5-HT) are terminated by reuptake via a Na + -dependent serotonin transporter (SERT) encoded by the SLC6A4 gene. The SERT is the target for an important class of antidepressant drugs (the serotonin selective reuptake inhibitors) and also of certain drugs of abuse including 3,4-Methylenedioxymethamphetamine (MDMA or 'ecstasy'). Polymorphisms in the SLC6A4 gene have been reported to be associated with depression and other psychiatric disorders and to influence personality traits (reviewed by Lesch 1 ). To facilitate studies of the molecular basis of these associations, we have constructed a map of a 1 Mb region encompassing the human SLC6A4 and CPD genes. We have evaluated the contribution of these genes to the phenotype observed in patients with NF1 contiguous gene deletions. Table 1 .
Materials and methods

Construction and analyses of physical contig
Patient and somatic cell hybrid lines
Patient UWA106-3 is hemizygous for a microdeletion of about 1-1.5 Mb that spans the entire NF1 gene. 4 The human/ rodent somatic hybrid cell lines UWA106-3-#36 and UWA106-3-#41 harbour, respectively, the deleted and nondeleted chromosomes 17 from this patient. 4 Fluorescence in situ hybridisation (FISH) was carried out with biotin-11-dATP-labelled 50G6 PAC DNA.
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Results
Characterisation of the SLC6A4 gene and PAC clones
Long-range PCR of human genomic DNA with six pairs of primers indicated that the SLC6A4 gene spanned approximately 40 kb (Table 1) . One PAC (50G6) contained the entire coding sequence of the SLC6A4 gene. Southern blot analysis of NotI digested 50G6 DNA revealed a 40 kb fragment that hybridised to end clone 28L, a 55 kb fragment that hybridised to end clone 24R, and a 16 kb fragment from the PAC vector (data not shown). We concluded that 50G6 contains the entire SLC6A4 gene flanked by about 40 kb of 5' sequence and about 15 kb of 3' sequence.
Construction of SLC6A4 contig
The contig depicted in Figure 1 was assembled by analysis of 6 YACs and the PAC 50G6 for the presence of 6 STS markers and for the PAC end clones 24R and 28L. Five of the six YACs harboured the entire SLC6A4 gene, whereas 704F1 lacked the 5' untranslated region and first exon. These data oriented the 3' end of the SLC6A4 gene towards the chromosome 17 centromere. D17S1294 mapped < 15 kb centromeric to the 3' end of the SLC6A4 gene, since it was present in 704F1 but not in 49A9. All clones carried the 10 repeat allele of SLC6A4 intron 2 polymorphism; 6 YAC clones from ICRF library carried the short allele of the promoter polymorphism, 7 while those from the CEPH library carried the long allele.
Carboxypeptidase D gene maps telomeric to SLC6A4
A 163 kb genomic sequence from human chromosome 17 (GenBank AC006050) encodes the entire CPD gene, with D17S2004 and D17S2009 within the predicted 3' untranslated region. The presence of the CPD gene in YACs 35D8, 765D1 and 49A9 was confirmed using both forward primers of D17S2009 and D17S2004 and with two pairs of primers (cpd6740F/cpd6858R, and cpd1065F/cpd1768R: Table 1) from CPD cDNA. We concluded that the CPD gene lies telomeric to the SLC6A4 gene within the contig.
Hemizygotic deletion of the SLC6A4 and CPD genes in a NF1 patient Our YAC contig does not contain the NF1 gene, since none of the YAC clones yielded products with PCR primer pairs from exons 1, 27a and 49.2 of the gene. 8 However, because the deletion in UWA106-3 included loci predicted to map nearer the centromere than SLC6A4 , we subjected metaphase chromosomes prepared from immortalised lymphoblasts of this patient to FISH using 50G6 as the probe. Only one hybridisation signal was observed, confirming the hemizygosity of the SLC6A4 locus (Figure 2a) . PCR of DNA from rodent/human somatic hybrid cell lines carrying either the deleted or non-deleted chromosomes 17 of UWA106-3 indicated that the deletion encompassed the CPD and SLC6A4 genes and D17S2120 but not D17S1294 or D17S1549 (Figure 2b) . Therefore, the centromeric breakpoint of the deletion in this patient lies in a < 15 kb region between exon 14 of the SLC6A4 gene and D17S1294 (arrow head, Figure 1b) . Neither the SLC6A4 nor the CPD gene was deleted in 16 additional NF1 microdeletion patients 4 examined.
Discussion
We report here the construction of a 1 Mb contig encompassing the SLC6A4 and CPD genes and eight marker loci. Our results confirm the localisation of SLC6A4 9,10 and CPD 11 to chromosome 17q11.2-17q12. The SLC6A4 and CPD genes were deleted in 1/17 NF1 microdeletion patients tested, but our data suggest that the majority of such patients will not be haploinsufficient for SERT and CPD. The identification of eight marker loci flanking the SLC6A4 and CPD genes will facilitate future studies of their role in susceptibility to developmental and psychiatric disorders. This contig will also provide a centromeric anchor for chromosomal walking towards the NF1 gene, which may lead to the discovery of other genes contiguous to NF1. Functional analysis of these The primers (see Table 1 and the Genome Database [http://gdbwww.gdb.org]) and sizes of PCR products are indicated. The specific PCR product of the E2F/2B primer pair is arrowed.
Mapping of the SLC6A4 gene adjacent to CPD and NF1 S Shen et al y genes should play a role in the understanding of neurofibromatosis as well as other developmental/psychiatric disorders.
